Body composition / abdominal-fat interest
Tesamorelin vs Semaglutide (injectable)
One has a narrow HIV-lipodystrophy VAT indication and the other obesity/diabetes evidence; compare populations and endpoints rather than 'belly fat'.
At a glance
Tesamorelin
Semaglutide (injectable)
Human evidence
Tesamorelin has strong evidence for its narrow HIV-associated abdominal-fat indication. A randomized HIV/NAFLD study also reduced liver fat substantially, while a small 2025 Phase II cognitive trial did not show significant between-group cognitive benefit.
Extensive Phase III evidence supports weight loss with regulated semaglutide. SELECT demonstrated cardiovascular benefit in a defined population, and STEP 9 showed improved knee-OA pain/function in adults with obesity.
Research focus
Excess abdominal visceral fat in adults with HIV and lipodystrophy
Obesity, weight management, cardiovascular outcomes, heart failure, osteoarthritis, type 2 diabetes
Regulatory status
FDA-licensed Egrifta formulations are indicated to reduce excess abdominal fat in adults with HIV and lipodystrophy; not a general weight-loss approval.
Wegovy (semaglutide) is authorised in the EU for weight management in defined adults and adolescents; authorisation and dosing are product-, route-, indication- and jurisdiction-specific.
Route / formulation
Research-market tesamorelin is not automatically equivalent to authorised Egrifta products.
Evidence for licensed pre-filled injection pens cannot establish identity, concentration, sterility or equivalence of unverified semaglutide vials or non-authorised products.
Not therapeutically equivalent; no simple head-to-head basis One has a narrow HIV-lipodystrophy VAT indication and the other obesity/diabetes evidence; compare populations and endpoints rather than 'belly fat' marketing.